Nowdiagnostics, Inc.

Springdale, AR Doing business as Now Diagnostics

UEI
KTYPNFNGG3E9
CAGE
7BC17
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1200 Stewart Pl, Springdale, AR 72764, USA
Website
nowdx.com
Founded
2014
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Health Care Equipment & Services
  3. Health Care Providers & Services
SIC code
38 Instruments & Related Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $0
FY2024 $0
FY2023 -$6

Contract awards

Grant awards

Award Agency Obligated Awarded
Device for preservation of cell free RNA in saliva R21CA258013 National Cancer Institute (NIH) $716,336

Similar vendors

About the company

Nowdiagnostics, Inc., doing business as Now Diagnostics, is a self-certified small disadvantaged business and manufacturer of goods registered to receive federal government awards since November 2014. The company specializes in developing rapid diagnostic testing solutions, particularly in the field of medical diagnostics. Now Diagnostics has demonstrated its ability to contribute to government initiatives in healthcare and medical research through both federal contract awards and grant sub-awards. Their expertise lies in creating innovative diagnostic technologies, with a focus on point-of-care and over-the-counter tests for various medical conditions, including infectious diseases.

In August 2020, Now Diagnostics was awarded a prime federal contract by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response. This $695,500 firm-fixed-price definitive contract focused on developing rapid and accurate point-of-care and over-the-counter tests for detecting SARS-CoV-2 antibodies in blood. The contract, part of the NOW Diagnostics COVID-19 Serology Testing program, aimed to expand COVID-19 serology testing capacity nationwide. The work, performed in Fayetteville, Arkansas, included achieving Emergency Use Authorization (EUA) for the developed tests. This contract highlights Now Diagnostics' ability to respond to urgent public health needs by creating innovative diagnostic solutions. The contract was not designated as a set-aside, indicating that Now Diagnostics competed in an open market for this opportunity.

Now Diagnostics has also participated in federal grant programs as a sub-awardee, demonstrating its involvement in advanced research and development projects in partnership with academic institutions. In one such instance, the company collaborated with the University of Arkansas on a project related to SARS-CoV-2 testing. As part of this sub-award, Now Diagnostics was tasked with evaluating yeast strains and polyclonal antibodies to compare their effectiveness as standards in lateral flow assays for SARS-CoV-2. The company's role included producing prototype SARS-CoV-2 tests using their patented ADEXUSDx platform and the multiepitope yeast developed by the prime awardee. This sub-grant illustrates Now Diagnostics' capacity to contribute to cutting-edge diagnostic technologies and its ability to work effectively within collaborative research environments.

Quick answers

Is Nowdiagnostics, Inc. registered in SAM.gov?

Yes. Nowdiagnostics, Inc.'s SAM.gov registration is active through January 6, 2027.

What is Nowdiagnostics, Inc.'s most recent federal award?

Nowdiagnostics, Inc.'s most recent federal grant award is Device for preservation of cell free RNA in saliva (R21CA258013), from National Cancer Institute (NIH), on June 3, 2021.

On GovTribe

See Nowdiagnostics, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors